Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2012, Article ID 784536, 13 pages
http://dx.doi.org/10.1155/2012/784536
Review Article

The Chylomicron: Relationship to Atherosclerosis

1Diabetes Institute of Ireland, Beacon Clinic, Sandyford, Dublin 18, Ireland
2Trinity College Dublin, Dublin 2, Ireland

Received 20 June 2011; Accepted 8 August 2011

Academic Editor: Manuel Castro Cabezas

Copyright © 2012 Gerald H. Tomkin and Daphne Owens. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Hockey, R. A. Anderson, V. R. Cook, R. R. Hantgan, and R. B. Weinberg, “Effect of the apolipoprotein A-IV Q360H polymorphism on postprandial plasma triglyceride clearance,” Journal of Lipid Research, vol. 42, no. 2, pp. 211–217, 2001. View at Google Scholar · View at Scopus
  2. I. Neeli, S. A. Siddiqi, S. Siddiqi et al., “Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 17974–17984, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. Y. Yao, S. Lu, Y. Huang et al., “Regulation of microsomal triglyceride transfer protein by apolipoprotein A-IV in newborn swine intestinal epithelial cells,” American Journal of Physiology, vol. 300, no. 2, pp. G357–G363, 2011. View at Publisher · View at Google Scholar · View at PubMed
  4. M. M. Hussain, R. K. Kancha, Z. Zhou, J. Luchoomun, H. Zu, and A. Bakillah, “Chylomicron assembly and catabolism: role of apolipoproteins and receptors,” Biochimica et Biophysica Acta, vol. 1300, no. 3, pp. 151–170, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. D. D. Black, “Development and Physiological Regulation of Intestinal Lipid Absorption. I. Development of intestinal lipid absorption: Cellular events in chylomicron assembly and secretion,” American Journal of Physiology, vol. 293, no. 3, pp. G519–G524, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. S. Kumar and C. M. Mansbach II, “Prechylomicron transport vesicle: isolation and partial characterization,” American Journal of Physiology, vol. 276, no. 2, pp. G378–G386, 1999. View at Google Scholar
  7. C. M. Mansbach and F. Gorelick, “Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons,” American Journal of Physiology, vol. 293, no. 4, pp. G645–G650, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. Z. G. Jiang, Y. Liu, M. M. Hussain, D. Atkinson, and C. J. McKnight, “Reconstituting initial events during the assembly of apolipoprotein B-containing lipoproteins in a cell-free system,” Journal of Molecular Biology, vol. 383, no. 5, pp. 1181–1194, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Iqbal and M. M. Hussain, “Intestinal lipid absorption,” American Journal of Physiology, vol. 296, no. 6, pp. E1183–E1194, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. W. Tong, E. Paradise, E. Kim et al., “Clinical investigations of SLx-4090 in combination with metformin in type 2 diabetes,” Diabetes Care, 2010, ADA abstracts. View at Google Scholar
  11. D. M. Wong, J. P. Webb, P. M. Malinowski, E. Xu, J. Macri, and K. Adeli, “Proteomic profiling of intestinal prechylomicron transport vesicle (PCTV)-associated proteins in an animal model of insulin resistance (94 char),” Journal of Proteomics, vol. 73, no. 7, pp. 1291–1305, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. Hsieh, C. Longuet, A. Maida et al., “Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36,” Gastroenterology, vol. 137, no. 3, pp. 997–1005.e4, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. J. Amiot, D. Knol, N. Cardinault et al., “Phytosterol ester processing in the small intestine: impact on cholesterol availability for absorption and chylomicron cholesterol incorporation in healthy humans,” Journal of Lipid Research, vol. 52, no. 6, pp. 1256–1264, 2011. View at Publisher · View at Google Scholar · View at PubMed
  14. A. B. Weinglass, M. Kohler, U. Schulte et al., “Extracellular loop C of NPC1L1 is important for binding to ezetimibe,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 32, pp. 11140–11145, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. L. Bozzetto, G. Annuzzi, G. D. Corte et al., “Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes,” Atherosclerosis, vol. 217, no. 1, pp. 142–148, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. D. Masuda, Y. Nakagawa-Toyama, K. Nakatani et al., “Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia,” European Journal of Clinical Investigation, vol. 39, no. 8, pp. 689–698, 2009. View at Publisher · View at Google Scholar · View at PubMed
  17. J. C. Sandoval, Y. Nakagawa-Toyama, D. Masuda et al., “Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 9, pp. 914–924, 2010. View at Google Scholar · View at Scopus
  18. F. Kern, “Normal plasma cholesterol in an 88-year-old man who eats 25 eggs a day. Mechanisms of adaptation,” New England Journal of Medicine, vol. 324, no. 13, pp. 896–899, 1991. View at Google Scholar · View at Scopus
  19. S. W. Altmann, H. R. Davis, L. J. Zhu et al., “Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption,” Science, vol. 303, no. 5661, pp. 1201–1204, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. H. R. Davis Jr., L. M. Hoos, G. Tetzloff et al., “Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in apoE-/- mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 841–849, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. H. R. Davis, R. S. Lowe, and D. R. Neff, “Effects of ezetimibe on atherosclerosis in preclinical models,” Atherosclerosis, vol. 215, no. 2, pp. 266–278, 2011. View at Publisher · View at Google Scholar · View at PubMed
  22. S. G. Lakoski, F. Xu, G. L. Vega et al., “Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 800–809, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. J. Tremblay, B. Lamarche, V. Lemelin et al., “Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men,” Journal of Lipid Research, vol. 52, no. 3, pp. 558–565, 2011. View at Publisher · View at Google Scholar · View at PubMed
  24. J.-H. Zhang, L. Ge, W. Qi et al., “The N-terminal domain of NPC1L1 protein binds cholesterol and plays essential roles in cholesterol uptake,” Journal of Biological Chemistry, vol. 286, no. 28, pp. 25088–25097, 2011. View at Publisher · View at Google Scholar · View at PubMed
  25. A. Gleeson, D. Owens, P. Collins, A. Johnson, and G. H. Tomkin, “The relationship between cholesterol absorption and intestinal cholesterol synthesis in the diabetic rat model,” Experimental Diabesity Research, vol. 1, no. 3, pp. 203–210, 2000. View at Google Scholar · View at Scopus
  26. S. Lally, D. Owens, and G. H. Tomkin, “Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats,” Metabolism, vol. 56, no. 3, pp. 430–438, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Lally, C. Y. Tan, D. Owens, and G. H. Tomkin, “Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein,” Diabetologia, vol. 49, no. 5, pp. 1008–1016, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. E. Levy, G. Lalonde, E. Delvin et al., “Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus,” Endocrinology, vol. 151, no. 3, pp. 958–970, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. E. Levy, S. Spahis, E. Ziv et al., “Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids,” Diabetologia, vol. 49, no. 8, pp. 1937–1945, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. Garcia-Calvo, J. Lisnock, H. G. Bull et al., “The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1),” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 23, pp. 8132–8137, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. W. Huff, R. L. Pollex, and R. A. Hegele, “NPC1L1: evolution from pharmacological target to physiological sterol transporter,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2433–2438, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. N. Van Der Veen, J. K. Kruit, R. Havinga et al., “Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1,” Journal of Lipid Research, vol. 46, no. 3, pp. 526–534, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. Z. Ashraf and N. Gupta, “Scavenger receptors: implications in atherothrombotic disorders,” International Journal of Biochemistry and Cell Biology, vol. 43, no. 5, pp. 697–700, 2011. View at Publisher · View at Google Scholar · View at PubMed
  34. K. E. Berge, H. Tian, G. A. Graf et al., “Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters,” Science, vol. 290, no. 5497, pp. 1771–1775, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. G. A. Graf, L. Yu, W. P. Li et al., “ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary excretion,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 48275–48282, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. A. Kosters, C. Kunne, N. Looije, S. B. Patel, R. P. J. Oude Elferink, and A. K. Groen, “The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice,” Journal of Lipid Research, vol. 47, no. 9, pp. 1959–1966, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. H. H. Wang, S. B. Patel, M. C. Carey, and D. Q. H. Wang, “Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8-/- mice,” Hepatology, vol. 45, no. 4, pp. 998–1006, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Santosa, I. Demonty, A. H. Lichtenstein, J. M. Ordovas, and P. J. H. Jones, “Single nucleotide polymorphisms in ABCG5 and ABCG8 are associated with changes in cholesterol metabolism during weight loss,” Journal of Lipid Research, vol. 48, no. 12, pp. 2607–2613, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. H. Gylling, M. Hallikainen, J. Pihlajamäki et al., “Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity,” Journal of Lipid Research, vol. 45, no. 9, pp. 1660–1665, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. V. W. Bloks, W. M. Bakker-Van Waarde, H. J. Verkade et al., “Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes,” Diabetologia, vol. 47, no. 1, pp. 104–112, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. S. Lally, D. Owens, and G. H. Tomkin, “The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes,” Atherosclerosis, vol. 193, no. 2, pp. 343–351, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. K. Y. Ma, N. Yang, R. Jiao et al., “Dietary calcium decreases plasma cholesterol by down-regulation of intestinal Niemann-Pick C1 like 1 and microsomal triacylglycerol transport protein and up-regulation of CYP7A1 and ABCG 5/8 in hamsters,” Molecular Nutrition and Food Research, vol. 55, no. 2, pp. 247–258, 2011. View at Publisher · View at Google Scholar · View at PubMed
  43. E. Kim, S. Campbell, O. Schueller et al., “A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 3, pp. 775–785, 2011. View at Publisher · View at Google Scholar · View at PubMed
  44. T. Hata, Y. Mera, Y. Ishii et al., “JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 3, pp. 850–856, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. D. Aggarwal, K. L. West, T. L. Zern, S. Shrestha, M. Vergara-Jimenez, and M. L. Fernandez, “JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs,” BMC Cardiovascular Disorders, vol. 5, article no. 30, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. C. Phillips, K. Mullan, D. Owens, and G. H. Tomkin, “Microsomal triglyceride transfer protein polymorphisms and lipoprotein levels in type 2 diabetes,” QJM, vol. 97, no. 4, pp. 211–218, 2004. View at Publisher · View at Google Scholar
  47. F. Karpe, B. Lundahl, E. Ehrenborg, P. Eriksson, and A. Hamsten, “A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 756–761, 1998. View at Google Scholar · View at Scopus
  48. C. Phillips, A. Bennett, K. Anderton et al., “Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes,” Metabolism, vol. 51, no. 7, pp. 847–852, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Gleeson, K. Anderton, D. Owens et al., “The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes,” Diabetologia, vol. 42, no. 8, pp. 944–948, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. B. Qin, W. Qiu, R. K. Avramoglu, and K. Adeli, “Tumor necrosis factor-α induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein b48-containing lipoproteins,” Diabetes, vol. 56, no. 2, pp. 450–461, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. M. Zoltowska, E. Ziv, E. Delvin et al., “Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2539–2545, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Bernard, S. Touzet, I. Personne et al., “Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes,” Diabetologia, vol. 43, no. 8, pp. 995–999, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. S. P. L. Chen, K. C. B. Tan, and K. S. L. Lam, “Effect of the microsomal triglyceride transfer protein -493 G/T polymorphism and type 2 diabetes mellitus on LDL subfractions,” Atherosclerosis, vol. 167, no. 2, pp. 287–292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Karpe, B. Lundahl, E. Ehrenborg, P. Eriksson, and A. Hamsten, “A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 756–761, 1998. View at Google Scholar · View at Scopus
  55. J. St-Pierre, I. Lemieux, I. Miller-Felix et al., “Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men,” Atherosclerosis, vol. 160, no. 2, pp. 317–324, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. S. H. H. Juo, Z. Han, J. D. Smith, L. Colangelo, and K. Liu, “Common polymorphism in promoter of microsomal triglyceride transfer protein gene influences cholesterol, ApoB, and triglyceride levels in young African American men: Results from the coronary artery risk development in young adults (CARDIA) study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 5, pp. 1316–1322, 2000. View at Google Scholar · View at Scopus
  57. H. Ledmyr, A. D. McMahon, E. Ehrenborg et al., “The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease,” Circulation, vol. 109, no. 19, pp. 2279–2284, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. J. Shepherd, S. M. Cobbe, I. Ford et al., “Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia,” New England Journal of Medicine, vol. 333, no. 20, pp. 1301–1307, 1995. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Lithell, H. Aberg, I. Selinus, and H. Hedstrand, “The Primary Preventive Study in Uppsala: fatal and non-fatal myocardial infarction during a 10-year follow-up of a middle-aged male population with treatment of high-risk individuals,” Acta Medica Scandinavica, vol. 215, no. 5, pp. 403–409, 1984. View at Google Scholar
  60. A. Aminoff, H. Ledmyr, P. Thulin et al., “Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease,” Journal of Lipid Research, vol. 51, no. 1, pp. 103–111, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. K. G. Bharadwaj, Y. Hiyama, Y. Hu et al., “Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake,” Journal of Biological Chemistry, vol. 285, no. 49, pp. 37976–37986, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. Y. Tan, T. Ichikawa, J. Li et al., “Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo,” Diabetes, vol. 60, no. 2, pp. 625–633, 2011. View at Publisher · View at Google Scholar · View at PubMed
  63. H. C. Chen and R. V. Farese Jr., “DGAT and triglyceride synthesis: a new target for obesity treatment?” Trends in Cardiovascular Medicine, vol. 10, no. 5, pp. 188–192, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. S. J. Smith, S. Cases, D. R. Jensen et al., “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat,” Nature Genetics, vol. 25, no. 1, pp. 87–90, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. H. C. Chen, S. J. Smith, Z. Ladha et al., “Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1,” Journal of Clinical Investigation, vol. 109, no. 8, pp. 1049–1055, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Yamamoto, H. Yamaguchi, H. Miki et al., “A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity,” vol. 650, no. 2-3, pp. 663–672, 2011. View at Publisher · View at Google Scholar · View at PubMed
  67. Y. Nakada, M. Ogino, K. Asano et al., “Novel acyl coenzyme A: dacylglycerol acyltransferase 1 inhibitors—synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides,” Chemical and Pharmaceutical Bulletin, vol. 58, no. 5, pp. 673–679, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre et al., “PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar · View at Scopus
  69. E. Raspé, H. Duez, A. Mansén et al., “Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription,” Journal of Lipid Research, vol. 43, no. 12, pp. 2172–2179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Staels, N. Vu-Dac, V. A. Kosykh et al., “Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 705–712, 1995. View at Google Scholar · View at Scopus
  71. A. Hiukka, J. Fruchart-Najib, E. Leinonen, H. Hilden, J. C. Fruchart, and M. R. Taskinen, “Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes,” Diabetologia, vol. 48, no. 6, pp. 1207–1215, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. J. C. Fruchart, “Peroxisome proliferator-activated receptor-alpha (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease,” Atherosclerosis, vol. 205, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. FIELD Study Investigators, “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Google Scholar
  74. G. Steiner, A. Hamsten, J. Hosking et al., “Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study,” Lancet, vol. 357, no. 9260, pp. 905–910, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. D. D. Black, “Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion,” American Journal of Physiology, vol. 293, no. 3, pp. G519–G524, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. S. Leng, S. Lu, Y. Yao et al., “Hepatocyte nuclear factor-4 mediates apolipoprotein A-IV transcriptional regulation by fatty acid in newborn swine enterocytes,” American Journal of Physiology, vol. 293, no. 2, pp. G475–G483, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. S. Lu, Y. Yao, X. Cheng et al., “Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size,” Journal of Biological Chemistry, vol. 281, no. 6, pp. 3473–3483, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. Y. Yao, S. Lu, Y. Huang et al., “Regulation of microsomal triglyceride transfer protein by apolipoprotein A-IV in newborn swine intestinal epithelial cells,” American Journal of Physiology, vol. 300, no. 2, pp. G357–G363, 2011. View at Publisher · View at Google Scholar · View at PubMed
  79. R. D. Cohen, L. W. Castellani, J. H. Qiao, B. J. Van Lenten, A. J. Lusis, and K. Reue, “Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV,” Journal of Clinical Investigation, vol. 99, no. 8, pp. 1906–1916, 1997. View at Google Scholar · View at Scopus
  80. F. Soriguer, S. García-Serrano, L. Garrido-Sánchez et al., “Jejunal wall triglyceride concentration of morbidly obese persons is lower in those with type 2 diabetes mellitus,” Journal of Lipid Research, vol. 51, no. 12, pp. 3516–3523, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. L. M. Federico, M. Naples, D. Taylor, and K. Adeli, “Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: Evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine,” Diabetes, vol. 55, no. 5, pp. 1316–1326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. W. S. Au, H. F. Kung, and M. C. Lin, “Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38,” Diabetes, vol. 52, no. 5, pp. 1073–1080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. D. L. Hagan, B. Kienzle, H. Jamil, and N. Hariharan, “Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type specific expression and response to metabolic regulators,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 28737–28744, 1994. View at Google Scholar · View at Scopus
  84. M. C. M. Lin, D. Gordon, and J. R. Wetterau, “Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression,” Journal of Lipid Research, vol. 36, no. 5, pp. 1073–1081, 1995. View at Google Scholar · View at Scopus
  85. D. M. Wong, J. P. Webb, P. M. Malinowski, E. Xu, J. Macri, and K. Adeli, “Proteomic profiling of intestinal prechylomicron transport vesicle (PCTV)-associated proteins in an animal model of insulin resistance (94 char),” Journal of Proteomics, vol. 73, no. 7, pp. 1291–1305, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. K. Dai, I. Khatun, and M. M. Hussain, “NR2F1 and IRE1β suppress microsomal triglyceride transfer protein expression and lipoprotein assembly in undifferentiated intestinal epithelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 3, pp. 568–574, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. S. J. Hernández-Vallejo, M. Alqub, S. Luquet et al., “Short-term adaptation of postprandial lipoprotein secretion and intestinal gene expression to a high-fat diet,” American Journal of Physiology, vol. 296, no. 4, pp. G782–G792, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. K. R. Steffensen and J. Å. Gustafsson, “Putative metabolic effects of the liver X receptor (LXR),” Diabetes, vol. 53, no. 1, pp. S36–S42, 2004. View at Google Scholar · View at Scopus
  89. P. J. Talmud, “Rare APOA5 mutations–clinical consequences, metabolic and functional effects: an ENID review,” Atherosclerosis, vol. 194, no. 2, pp. 287–292, 2007. View at Google Scholar
  90. M. Guardiola, A. Alvaro, J. C. Vallvé et al., “APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate,” Nutrition, Metabolism and Cardiovascular Diseases. In press. View at Publisher · View at Google Scholar · View at PubMed
  91. P. Dandona, R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada, and T. Wadden, “Tumor necrosis factor-α in sera of obese patients: fall with weight loss,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 8, pp. 2907–2910, 1998. View at Publisher · View at Google Scholar
  92. B. Qin, W. Qiu, R. K. Avramoglu, and K. Adeli, “Tumor necrosis factor-α induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein b48-containing lipoproteins,” Diabetes, vol. 56, no. 2, pp. 450–461, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. B. Qin, R. A. Anderson, and K. Adeli, “Tumor necrosis factor-α directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling,” American Journal of Physiology, vol. 294, no. 5, pp. G1120–G1129, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. B. Qin, H. Dawson, and R. A. Anderson, “Elevation of tumor necrosis factor-α induces the overproduction of postprandial intestinal apolipoprotein B48-containing very low-density lipoprotein particles: evidence for related gene expression of inflammatory, insulin and lipoprotein signaling in enterocytes,” Experimental Biology and Medicine, vol. 235, no. 2, pp. 199–205, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. A. Laatsch, M. Merkel, P. J. Talmud, T. Grewal, U. Beisiegel, and J. Heeren, “Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance,” Atherosclerosis, vol. 204, no. 1, pp. 105–111, 2009. View at Publisher · View at Google Scholar · View at PubMed
  96. C. Pramfalk, Z. Y. Jiang, Q. Cai et al., “HNF1α and SREBP2 are important regulators of NPC1L1 in human liver,” Journal of Lipid Research, vol. 51, no. 6, pp. 1354–1362, 2010. View at Publisher · View at Google Scholar · View at PubMed
  97. L. Jia, J. L. Betters, and L. Yu, “Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport,” Annual Review of Physiology, vol. 73, pp. 239–259, 2011. View at Publisher · View at Google Scholar · View at PubMed
  98. W. Cui, Z. Y. Jiang, Q. Cai et al., “Decreased NPC1L1 expression in the liver from Chinese female gallstone patients,” Lipids in Health and Disease, vol. 9, article no. 17, 2010. View at Publisher · View at Google Scholar · View at PubMed
  99. M. A. Valasek, J. J. Repa, G. Quan, J. M. Dietschy, and S. D. Turley, “Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters,” American Journal of Physiology, vol. 295, no. 4, pp. G813–G822, 2008. View at Publisher · View at Google Scholar · View at PubMed
  100. S. Zúñiga, H. Molina, L. Azocar et al., “Ezetimibe prevents cholesterol gallstone formation in mice,” Liver International, vol. 28, no. 7, pp. 935–947, 2008. View at Publisher · View at Google Scholar · View at PubMed
  101. L. Jia, Y. Ma, S. Rong et al., “Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis,” Journal of Lipid Research, vol. 51, no. 11, pp. 3135–3144, 2010. View at Publisher · View at Google Scholar · View at PubMed
  102. M. Nomura, H. Ishii, A. Kawakami, and M. Yoshida, “Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance,” American Journal of Physiology, vol. 297, no. 5, pp. E1030–E1038, 2009. View at Publisher · View at Google Scholar · View at PubMed
  103. M. Kishimoto, T. Sugiyama, K. Osame, D. Takarabe, M. Okamoto, and M. Noda, “Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes,” Journal of Medical Investigation, vol. 58, no. 1-2, pp. 86–94, 2011. View at Google Scholar
  104. K. J. Williams, “Molecular processes that handle—and mishandle—dietary lipids,” Journal of Clinical Investigation, vol. 118, no. 10, pp. 3247–3259, 2008. View at Publisher · View at Google Scholar · View at PubMed
  105. R. W. Mahley and Y. Huang, “Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 94–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
  106. R. W. Mahley and Z. S. Ji, “Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E,” Journal of Lipid Research, vol. 40, no. 1, pp. 1–16, 1999. View at Google Scholar
  107. B. J. Zeng, B. C. Mortimer, I. J. Martins, U. Seydel, and T. G. Redgrave, “Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes,” Journal of Lipid Research, vol. 39, no. 4, pp. 845–860, 1998. View at Google Scholar
  108. K. I. Stanford, J. R. Bishop, E. M. Foley et al., “Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice,” Journal of Clinical Investigation, vol. 119, no. 11, pp. 3236–3245, 2009. View at Publisher · View at Google Scholar · View at PubMed
  109. A. P. Beigneux, B. S. J. Davies, P. Gin et al., “Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons,” Cell Metabolism, vol. 5, no. 4, pp. 279–291, 2007. View at Publisher · View at Google Scholar · View at PubMed
  110. B. S. J. Davies, A. P. Beigneux, R. H. Barnes et al., “GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries,” Cell Metabolism, vol. 12, no. 1, pp. 42–52, 2010. View at Publisher · View at Google Scholar · View at PubMed
  111. J. R. Bishop, M. R. Passos-Bueno, L. Fong et al., “Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans,” PLoS One, vol. 5, no. 11, Article ID e13919, 2010. View at Publisher · View at Google Scholar · View at PubMed
  112. F. Karpe, G. Steiner, K. Uffelman, T. Olivecrona, and A. Hamsten, “Postprandial lipoproteins and progression of coronary atherosclerosis,” Atherosclerosis, vol. 106, no. 1, pp. 83–97, 1994. View at Publisher · View at Google Scholar
  113. S. D. Proctor and J. C. L. Mamo, “Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1595–1600, 2003. View at Publisher · View at Google Scholar · View at PubMed
  114. S. Pal, K. Semorine, G. F. Watts, and J. Mamo, “Identification of lipoproteins of intestinal origin in human atherosclerotic plaque,” Clinical Chemistry and Laboratory Medicine, vol. 41, no. 6, pp. 792–795, 2003. View at Publisher · View at Google Scholar · View at PubMed
  115. T. Nakano, K. Nakajima, M. Niimi et al., “Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases,” Clinica Chimica Acta, vol. 390, no. 1-2, pp. 38–43, 2008. View at Publisher · View at Google Scholar · View at PubMed
  116. C. H. Floren and A. Chait, “Uptake of chylomicron remnants by the native LDL receptor in human monocyte-derived macrophages,” Biochimica et Biophysica Acta, vol. 665, no. 3, pp. 608–611, 1981. View at Google Scholar
  117. S. H. Gianturco, M. P. Ramprasad, A. H. Y. Lin, R. Song, and W. A. Bradley, “Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells,” Journal of Lipid Research, vol. 35, no. 9, pp. 1674–1687, 1994. View at Google Scholar
  118. S. H. Gianturco, S. A. Brown, D. P. Via, and W. A. Bradley, “The β-VLDL receptor pathway of murine P388D1 macrophages,” Journal of Lipid Research, vol. 27, no. 4, pp. 412–420, 1986. View at Google Scholar
  119. C. L. Elsegood, S. Pal, P. D. Roach, and J. C. L. Mamo, “Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins,” Clinical Science, vol. 101, no. 2, pp. 111–119, 2001. View at Publisher · View at Google Scholar
  120. C. L. Elsegood and J. C. L. Mamo, “An investigation by electron microscopy of chylomicron remnant uptake by human monocyte-derived macrophages,” Atherosclerosis, vol. 188, no. 2, pp. 251–259, 2006. View at Publisher · View at Google Scholar · View at PubMed
  121. J. S. Cohn, “Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?” Atherosclerosis Supplements, vol. 9, no. 2, pp. 15–18, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. R. Mangat, J. W. Su, J. E. Lambert et al., “Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans,” Diabetic Medicine, vol. 28, no. 1, pp. 61–72, 2011. View at Publisher · View at Google Scholar · View at PubMed
  123. C. Phillips, G. Murugasu, D. Owens, P. Collins, A. Johnson, and G. H. Tomkin, “Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes,” Atherosclerosis, vol. 148, no. 2, pp. 283–291, 2000. View at Publisher · View at Google Scholar
  124. A. Curtin, P. Deegan, D. Owens, P. Collins, A. Johnson, and G. H. Tomkin, “Elevated triglyceride-rich lipoproteins in diabetes,” Acta Diabetologica, vol. 33, no. 3, pp. 205–210, 1996. View at Publisher · View at Google Scholar
  125. N. Mero, M. Syvänne, and M. -R. Taskinen, “Postprandial lipid metabolism in diabetes,” Atherosclerosis, vol. 141, supplement 1, pp. S53–S55, 1998. View at Google Scholar
  126. N. Mero, R. Malmström, G. Steiner, M. R. Taskinen, and M. Syvänne, “Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease,” Atherosclerosis, vol. 150, no. 1, pp. 167–177, 2000. View at Google Scholar